201. Temozolomide treatment of refractory epilepsy in a patient with an oligodendroglioma.
- Author
-
Ngo L, Nei M, and Glass J
- Subjects
- Adult, Anticonvulsants therapeutic use, Brain Neoplasms diagnosis, Brain Neoplasms epidemiology, Comorbidity, Dacarbazine therapeutic use, Drug Resistance, Epilepsy diagnosis, Humans, Magnetic Resonance Imaging, Male, Oligodendroglioma diagnosis, Oligodendroglioma epidemiology, Temozolomide, Treatment Outcome, Antineoplastic Agents, Alkylating therapeutic use, Brain Neoplasms drug therapy, Dacarbazine analogs & derivatives, Epilepsy drug therapy, Oligodendroglioma drug therapy
- Abstract
A 40-year-old man with a left frontotemporal grade II oligodendroglioma developed seizures that were refractory to 14 antiepileptic medications, the ketogenic diet, and epilepsy surgery. With temozolomide therapy, his seizure frequency gradually changed from 30 partial seizures per day to a single simple partial seizure in 6 months. No additional therapeutic measures were introduced during this time. This reduction in seizure frequency appears attributable solely to temozolomide therapy.
- Published
- 2006
- Full Text
- View/download PDF